Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation.

MLA

Deininger, Michael W., et al. “Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation.” Clinical Lymphoma, Myeloma & Leukemia, vol. 19, Sept. 2019, pp. S289–90. EBSCOhost, https://doi.org/10.1016/j.clml.2019.07.234.

APA

Deininger, M. W., Réa, D., Lang, F., Kim, D.-W., Cortes, J. E., Hughes, T. P., Minami, H., Breccia, M., DeAngelo, D. J., Hochhaus, A., Talpaz, M., Goh, Y. T., Le Coutre, P. D., Etienne, G., Sondhi, M., Mishra, K., Aimone, P., & Mauro, M. J. (2019). Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation. Clinical Lymphoma, Myeloma & Leukemia, 19, S289–S290. https://doi.org/10.1016/j.clml.2019.07.234

Chicago

Deininger, Michael W., Delphine Réa, Fabian Lang, Dong-Wook Kim, Jorge E. Cortes, Timothy P. Hughes, Hironobu Minami, et al. 2019. “Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation.” Clinical Lymphoma, Myeloma & Leukemia 19 (September): S289–90. doi:10.1016/j.clml.2019.07.234.